Anti-HPV18 E7/Protein E7 Antibody (SAA2229)
Biological Function
The Anti-HPV18 E7/Protein E7 Antibody (SAA2229) is a highly specific and sensitive monoclonal antibody that targets the E7 protein of the human papillomavirus type 18 (HPV18). This protein is known to play a crucial role in the development and progression of cervical cancer, making it a key target for therapeutic and diagnostic purposes.
Main Applications
This antibody is primarily used in research studies and clinical applications related to HPV18 and cervical cancer. It can be used for the detection and quantification of E7 protein in various samples, including tissue lysates, cell lysates, and body fluids. It can also be used in immunohistochemistry and immunofluorescence assays to visualize the distribution and expression of E7 protein in tissues.
Experimental Use Cases
The Anti-HPV18 E7/Protein E7 Antibody (SAA2229) has been extensively used in various experimental settings to study the role of E7 protein in HPV18-associated diseases. It has been used to investigate the mechanisms of E7-induced cell transformation, as well as to evaluate the efficacy of potential anti-HPV18 therapies. Additionally, this antibody has been used in clinical trials to assess the expression levels of E7 protein in cervical cancer patients and its correlation with disease progression.
With its high specificity and sensitivity, the Anti-HPV18 E7/Protein E7 Antibody (SAA2229) is a valuable tool for researchers and clinicians studying HPV18 and cervical cancer. Its reliable performance and ease of use make it an essential component in the fight against this deadly disease.
Keywords: Anti-HPV18 E7/Protein E7 Antibody, monoclonal antibody, human papillomavirus type 18, cervical cancer, E7 protein, therapeutic, diagnostic, research, clinical applications, immunohistochemistry, immunofluorescence, cell transformation, anti-HPV18 therapies, clinical trials, disease progression, specificity, sensitivity, reliable, essential.
There are no reviews yet.